Literature DB >> 11346124

Dry eye in the elderly.

M A Terry1.   

Abstract

Dry eye in the elderly population is a condition with a multitude of contributing factors and a wide spectrum of severity. The complex tear film is made up of layers of oil, aqueous and mucin, produced by the meibomian glands, main and accessory lacrimal glands, and by the goblet cells, respectively. Alteration in the normal function of any of these structures by disease, trauma or the environment can cause dysfunction of the tear film and result in the symptoms of dry eye (such as burning, grittiness and blurred vision). Normal lid anatomy and closure is critical to prevent evaporation of the normal tear film. The mainstay of current therapy is augmentation of the tear film with artificial tears and ointment. More severe cases of dry eye may require occlusion of the tear drainage system with plugs or electrocautery scarring. Good lid hygiene is also important for tear film health. A new paradigm of dry eye as a subclinical inflammatory disease has recently been suggested, and preliminary results from treatment with topical cyclosporin formulations are encouraging. The next few years promise exciting advances and relief for patients suffering from this chronic condition.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11346124     DOI: 10.2165/00002512-200118020-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  10 in total

1.  Schirmer's test. A closer look.

Authors:  T E Clinch; D A Benedetto; N T Felberg; P R Laibson
Journal:  Arch Ophthalmol       Date:  1983-09

2.  New treatment of dry eye: the effect of calcium ointment through eyelid skin delivery.

Authors:  K Tsubota; Y Monden; Y Yagi; E Goto; S Shimmura
Journal:  Br J Ophthalmol       Date:  1999-07       Impact factor: 4.638

3.  Prevalence of dry eye among the elderly.

Authors:  O D Schein; B Muñoz; J M Tielsch; K Bandeen-Roche; S West
Journal:  Am J Ophthalmol       Date:  1997-12       Impact factor: 5.258

4.  Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.

Authors:  D Stevenson; J Tauber; B L Reis
Journal:  Ophthalmology       Date:  2000-05       Impact factor: 12.079

5.  Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.

Authors:  K Sall; O D Stevenson; T K Mundorf; B L Reis
Journal:  Ophthalmology       Date:  2000-04       Impact factor: 12.079

Review 6.  The pathology of dry eye: the interaction between the ocular surface and lacrimal glands.

Authors:  M E Stern; R W Beuerman; R I Fox; J Gao; A K Mircheff; S C Pflugfelder
Journal:  Cornea       Date:  1998-11       Impact factor: 2.651

7.  The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical Cyclosporin A therapy.

Authors:  J Gao; T A Schwalb; J V Addeo; C R Ghosn; M E Stern
Journal:  Cornea       Date:  1998-11       Impact factor: 2.651

8.  Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome.

Authors:  P Marsh; S C Pflugfelder
Journal:  Ophthalmology       Date:  1999-04       Impact factor: 12.079

9.  The effect of ageing and disease on tear constituents.

Authors:  D V Seal
Journal:  Trans Ophthalmol Soc U K       Date:  1985

Review 10.  Tear physiology and dry eyes.

Authors:  F J Holly; M A Lemp
Journal:  Surv Ophthalmol       Date:  1977 Sep-Oct       Impact factor: 6.048

  10 in total
  13 in total

Review 1.  Effects of Aging in Dry Eye.

Authors:  Cintia S de Paiva
Journal:  Int Ophthalmol Clin       Date:  2017

2.  One month use of Systane improves ocular surface parameters in subjects with moderate symptoms of ocular dryness.

Authors:  Piera Versura; Vincenzo Profazio; Emilio C Campos
Journal:  Clin Ophthalmol       Date:  2008-09

3.  Lacrimal Gland Inflammation Deregulates Extracellular Matrix Remodeling and Alters Molecular Signature of Epithelial Stem/Progenitor Cells.

Authors:  Takeshi Umazume; William M Thomas; Sabrina Campbell; Hema Aluri; Suharika Thotakura; Driss Zoukhri; Helen P Makarenkova
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

Review 4.  The ocular surface immune system through the eyes of aging.

Authors:  Jeremias G Galletti; Cintia S de Paiva
Journal:  Ocul Surf       Date:  2021-02-20       Impact factor: 5.033

5.  Topical rebamipide improves the ocular surface in mild lagophthalmos.

Authors:  Mariko Itakura; Hirotaka Itakura; Tomoyuki Kashima; Hideo Akiyama; Shoji Kishi
Journal:  Clin Ophthalmol       Date:  2013-07-01

Review 6.  Age-related changes in ocular mucosal tolerance: Lessons learned from gut and respiratory tract immunity.

Authors:  Jeremias G Galletti; Cintia S de Paiva
Journal:  Immunology       Date:  2021-05-02       Impact factor: 7.215

7.  Effect of water-in-oil microemulsions and lamellar liquid crystalline systems on the precorneal tear film of albino New Zealand rabbits.

Authors:  Judy Chan; Gamal M El Maghraby; Jennifer P Craig; Raid G Alany
Journal:  Clin Ophthalmol       Date:  2008-03

8.  A randomized clinical evaluation of the safety of Systane Lubricant Eye Drops for the relief of dry eye symptoms following LASIK refractive surgery.

Authors:  Daniel Durrie; Jason Stahl
Journal:  Clin Ophthalmol       Date:  2008-12

9.  Etiology, prevalence, and treatment of dry eye disease.

Authors:  Johnny L Gayton
Journal:  Clin Ophthalmol       Date:  2009-07-14

10.  The dry eye disease activity log study.

Authors:  Jayant V Iyer; Sze-Yee Lee; Louis Tong
Journal:  ScientificWorldJournal       Date:  2012-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.